Membrane transporters in drug development
暂无分享,去创建一个
M. Niemi | Y. Sugiyama | K. Giacomini | Shiew-Mei Huang | D. Tweedie | L. Benet | K. Brouwer | X. Chu | A. Dahlin | R. Evers | V. Fischer | K. Hillgren | K. Hoffmaster | T. Ishikawa | D. Keppler | R. Kim | Caroline A. Lee | J. Polli | P. Swaan | J. Ware | S. Wright | S. Yee | M. J. Zamek-Gliszczynski | Lei Zhang | M. Zamek-Gliszczynski
[1] J. Cumings. Biochemical aspects. , 1962, Proceedings of the Royal Society of Medicine.
[2] E. P. Lewis. In perspective. , 1972, Nursing outlook.
[3] P. Fenster,et al. Digoxin-quinidine interaction. , 1979, Annals of internal medicine.
[4] D. Perrier,et al. Digoxin-quinidine interaction Pharmacokinetic evaluation. , 1979, New England Journal of Medicine.
[5] D. A. Page,et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans , 1982, Antimicrobial Agents and Chemotherapy.
[6] J. Baron,et al. 99mTc‐HIDA Cholescintigraphy in Children with Dubin‐Johnson Syndrome , 1983, Journal of pediatric gastroenterology and nutrition.
[7] H Rameis,et al. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? , 1985, International journal of clinical pharmacology, therapy, and toxicology.
[8] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[9] A. Somogyi,et al. Pharmacokinetic Interactions of Cimetidine 1987 , 1987, Clinical pharmacokinetics.
[10] A. Somogyi,et al. Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.
[11] A. Somogyi,et al. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans , 1992, Clinical pharmacology and therapeutics.
[12] R. Kramer,et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.
[13] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[14] K. Audus,et al. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. , 1994, The American journal of physiology.
[15] Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography , 1995, Hepatology.
[16] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[17] P. Borst,et al. Multidrug resistance and the role of P-glycoprotein knockout mice. , 1995, European journal of cancer.
[18] L. Benet,et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.
[19] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[20] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Keppler,et al. Transport function and substrate specificity of multidrug resistance protein. , 1998, Methods in enzymology.
[22] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[23] V. Sasseville,et al. A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.
[24] H. Yawo,et al. Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.
[25] I. Pastan,et al. Studies of Human MDR1-MDR2 Chimeras Demonstrate the Functional Exchangeability of a Major Transmembrane Segment of the Multidrug Transporter and Phosphatidylcholine Flippase , 1999, Molecular and Cellular Biology.
[26] Bruno Stieger,et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[27] K. Cundy. Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir , 1999, Clinical pharmacokinetics.
[28] C. Wandel,et al. Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.
[29] D. Keppler,et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[30] H. Kasanuki,et al. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans , 2000, Clinical pharmacology and therapeutics.
[31] M. Eve,et al. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. , 2000, British journal of clinical pharmacology.
[32] P. Meier,et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. , 2001, Gastroenterology.
[33] Shiew-Mei Huang,et al. Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus , 2001 .
[34] EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[35] J. Hochman,et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.
[36] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[37] D. Keppler,et al. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.
[38] Y Zhang,et al. The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.
[39] L. Benet,et al. The drug efflux-metabolism alliance: biochemical aspects. , 2001, Advanced drug delivery reviews.
[40] J B Houston,et al. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.
[41] H. Koepsell,et al. Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.
[42] R. Kim,et al. Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.
[43] L Landmann,et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.
[44] L. Benet,et al. Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.
[45] J. Schellens,et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Tracleer (bosentan). , 2002, Journal of clinical hypertension.
[47] Yuichi Sugiyama,et al. Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[48] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[49] Andreas Rolfs,et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.
[50] P. Meier,et al. The superfamily of organic anion transporting polypeptides. , 2003, Biochimica et biophysica acta.
[51] A. Schinkel,et al. Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.
[52] A. Schinkel,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.
[53] P. Gros,et al. Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide-binding domains of P-glycoprotein. , 2003, Biochemistry.
[54] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[55] Yuichi Sugiyama,et al. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.
[56] T. Abe,et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[57] Vijay K Gombar,et al. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.
[58] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[59] M. Gekle,et al. Action of EGF and PGE2 on basolateral organic anion uptake in rabbit proximal renal tubules and hOAT1 expressed in human kidney epithelial cells. , 2004, American journal of physiology. Renal physiology.
[60] H. Koepsell,et al. The SLC22 drug transporter family , 2004, Pflügers Archiv.
[61] K. Maeda,et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.
[62] P. Neuvonen,et al. Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression , 2004, Clinical pharmacology and therapeutics.
[63] D. Clarke,et al. Val133 and Cys137 in Transmembrane Segment 2 Are Close to Arg935 and Gly939 in Transmembrane Segment 11 of Human P-glycoprotein* , 2004, Journal of Biological Chemistry.
[64] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[65] W. Haefeli,et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers , 2004, Clinical pharmacology and therapeutics.
[66] K. Brouwer,et al. P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide , 2004, Pharmaceutical Research.
[67] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[68] D. Keppler,et al. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.
[69] S. Bates,et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2 , 2005, Cancer Chemotherapy and Pharmacology.
[70] Y. Sugiyama,et al. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. , 2004, Molecular pharmacology.
[71] Paul D. Martin,et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.
[72] Yuichi Sugiyama,et al. Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver , 2000, Pharmaceutical Research.
[73] N. Makita,et al. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access. , 2004, Molecular pharmacology.
[74] W. Vaalburg,et al. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein , 2004, Cancer Chemotherapy and Pharmacology.
[75] A. V. van Herwaarden,et al. Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.
[76] Mikko Niemi,et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[77] A. V. van Herwaarden,et al. The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.
[78] T. Ishikawa,et al. High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. , 2005, Methods in enzymology.
[79] D. Mankoff,et al. Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.
[80] D. Keppler,et al. Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2 , 2005, Journal of Pharmacology and Experimental Therapeutics.
[81] S. Wright. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. , 2005, Toxicology and applied pharmacology.
[82] Caroline A. Lee,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.
[83] Y. Sai,et al. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. , 2005, Drug metabolism and pharmacokinetics.
[84] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[85] R. Neubert,et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.
[86] Sean Ekins,et al. In Vitro and Pharmacophore-Based Discovery of Novel hPEPT1 Inhibitors , 2005, Pharmaceutical Research.
[87] D. Oh,et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.
[88] Yi Zhang,et al. BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers , 2005, Pharmaceutical Research.
[89] V. Mandys,et al. Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. , 2005, Gastroenterology.
[90] Yuichi Sugiyama,et al. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.
[91] D. Keppler. Uptake and efflux transporters for conjugates in human hepatocytes. , 2005, Methods in enzymology.
[92] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[93] Organic Cation Transporters , 2006 .
[94] Kim L R Brouwer,et al. The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice , 2006, Molecular Pharmacology.
[95] Kim L. R. Brouwer,et al. Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.
[96] A. V. van Herwaarden,et al. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. , 2006, Trends in pharmacological sciences.
[97] M. Shelton,et al. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.
[98] Alfred H. Schinkel,et al. BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION , 2006, Drug Metabolism and Disposition.
[99] Thomas J. Raub,et al. P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.
[100] J. Schellens,et al. Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[101] X. Chu,et al. Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2) , 2006, Journal of Pharmacology and Experimental Therapeutics.
[102] M. Jerling. Clinical Pharmacokinetics of Ranolazine , 2006, Clinical pharmacokinetics.
[103] Sean Ekins,et al. Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.
[104] John R Zalcberg,et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] P. Manley,et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.
[106] Supratim Choudhuri,et al. Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters , 2006, International journal of toxicology.
[107] P. Neuvonen,et al. Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.
[108] P. Sinko,et al. siRNA--getting the message out. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[109] G. Mann,et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Meng Li,et al. Drugdrug interactions involving membrane transporters in the human kidney , 2006, Expert opinion on drug metabolism & toxicology.
[111] Hiroyuki Hirano,et al. A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[112] G. Burckhardt,et al. Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles , 2007, Pharmaceutical Research.
[113] V. Vallon,et al. Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice* , 2006, Journal of Biological Chemistry.
[114] I. Cascorbi,et al. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. , 2006, Pharmacology & therapeutics.
[115] A. Fujimura,et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: First case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 , 2006, Clinical pharmacology and therapeutics.
[116] R. Kim,et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics , 2006, Clinical pharmacology and therapeutics.
[117] Shiew-Mei Huang,et al. Scientific perspectives on drug transporters and their role in drug interactions. , 2006, Molecular pharmaceutics.
[118] K. Maeda,et al. DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.
[119] J. Ware,et al. Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.
[120] Kazuya Maeda,et al. PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.
[121] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[122] T. Ishikawa,et al. Human ABC Transporter ABCG2 in Xenobiotic Protection and Redox Biology , 2006, Drug metabolism reviews.
[123] Kazuya Maeda,et al. In Vitro–In Vivo Scale‐up of Drug Transport Activities , 2006 .
[124] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[125] M. Hidalgo,et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.
[126] Mikko Niemi,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.
[127] Yuichi Sugiyama,et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[128] I. Cascorbi,et al. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[129] Balram Chowbay,et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.
[130] Ya-li Liu,et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[131] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[132] U. Wolfrum,et al. Caki-1 Cells Represent an in vitro Model System for Studying the Human Proximal Tubule Epithelium , 2007, Nephron Experimental Nephrology.
[133] Jos H Beijnen,et al. P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan , 2007, Clinical Cancer Research.
[134] H. Koepsell,et al. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.
[135] P. Neuvonen,et al. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.
[136] Kimura Yasuhisa,et al. Mechanism of multidrug recognition by MDR1/ABCB1 , 2007 .
[137] Yuichi Sugiyama,et al. Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens , 2007, Molecular Pharmacology.
[138] B. Stieger,et al. Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.
[139] K. Brouwer,et al. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. , 2007, Molecular pharmaceutics.
[140] Shuzhong Zhang,et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.
[141] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[142] S. Nigam,et al. Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues , 2007, Nature Clinical Practice Nephrology.
[143] K. Audus,et al. Low-affinity uptake of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (4-Di-1-ASP) in BeWo cells. , 2007, Biochemical pharmacology.
[144] I. Tamai,et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. , 2007, Life sciences.
[145] T. Kikukawa,et al. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[146] Per Artursson,et al. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.
[147] P Chiba,et al. Future directions for drug transporter modelling , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[148] C. Funk,et al. Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 , 2007, Drug Metabolism and Disposition.
[149] T. Terasaki,et al. Multichannel Liquid Chromatography–Tandem Mass Spectrometry Cocktail Method for Comprehensive Substrate Characterization of Multidrug Resistance-Associated Protein 4 Transporter , 2007, Pharmaceutical Research.
[150] P. Swaan,et al. Structural Variation Governs Substrate Specificity for Organic Anion Transporter (OAT) Homologs , 2007, Journal of Biological Chemistry.
[151] P. Manley,et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. , 2007, Blood.
[152] J. Timmer,et al. Data-Based Mathematical Modeling of Vectorial Transport across Double-Transfected Polarized Cells , 2007, Drug Metabolism And Disposition.
[153] R. Sheridan,et al. Mini review on molecular modeling of P-glycoprotein (Pgp). , 2007, Current topics in medicinal chemistry.
[154] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[155] W. Heizer,et al. In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans , 2007, Clinical pharmacology and therapeutics.
[156] Medical Product Development and Regulatory Science for the 21st Century: The Critical Path Vision and Its Impact on Health Care , 2007, Clinical pharmacology and therapeutics.
[157] H. Kusuhara,et al. Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.
[158] K. Ueda,et al. Mechanism of multidrug recognition by MDR1/ABCB1. , 2007, Cancer science.
[159] L. Chinn,et al. ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.
[160] Sang Chung,et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process , 2008, Journal of clinical pharmacology.
[161] David S. Miller,et al. Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy , 2008, Pharmacological Reviews.
[162] O. Ogawa,et al. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. , 2008, American journal of physiology. Renal physiology.
[163] P. Neuvonen,et al. Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.
[164] Physiology, structure, and regulation of the cloned organic anion transporters. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[165] C. Gui,et al. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[166] Supratim Choudhuri,et al. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[167] K. Giacomini,et al. Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.
[168] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[169] V. Vallon,et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. , 2008, American journal of physiology. Renal physiology.
[170] S‐M Huang,et al. Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice , 2008, Clinical pharmacology and therapeutics.
[171] J. Schellens,et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.
[172] K. Hillgren,et al. PhRMA White Paper on ADME Pharmacogenomics , 2008, Journal of clinical pharmacology.
[173] Bo Feng,et al. In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.
[174] R. Mehvar,et al. Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin , 2008, Journal of cardiovascular pharmacology.
[175] R. Kim,et al. Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin , 2008, Molecular Pharmacology.
[176] Kazuya Maeda,et al. Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans , 2008, Drug Metabolism and Disposition.
[177] A. Sparreboom,et al. Pharmacogenomic importance of ABCG2. , 2008, Pharmacogenomics.
[178] Christel A. S. Bergström,et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.
[179] Peter J H Webborn,et al. Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.
[180] B. Feng,et al. Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.
[181] S. Bates,et al. ABCG2: structure, function and role in drug response , 2008 .
[182] S-F Zhou,et al. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[183] Shiew-Mei Huang,et al. A regulatory viewpoint on transporter-based drug interactions , 2008 .
[184] Joe Palandra,et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.
[185] Yi Wang,et al. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.
[186] K. Brouwer,et al. Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies , 2008, Pharmaceutical Research.
[187] A. van Waarde,et al. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. , 2008, Nuclear medicine and biology.
[188] Yuichi Sugiyama,et al. Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.
[189] Meng Li,et al. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[190] P. Swaan,et al. Multi-level Analysis of Organic Anion Transporters 1, 3, and 6 Reveals Major Differences in Structural Determinants of Antiviral Discrimination* , 2008, Journal of Biological Chemistry.
[191] Rui Gao,et al. Pharmacogenetics of membrane transporters: a review of current approaches. , 2008, Methods in molecular biology.
[192] U. B. Nair,et al. Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein , 2008, Anesthesiology.
[193] Brian Tomlinson,et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.
[194] A. Fujimura,et al. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. , 2008, European journal of pharmacology.
[195] S. Bates,et al. ABCG2: structure, function and role in drug response. , 2008, Expert opinion on drug metabolism & toxicology.
[196] J. Gerber,et al. Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers , 2008, Journal of acquired immune deficiency syndromes.
[197] Organic cation transporters. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[198] C. Gui,et al. Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. , 2008, Biochemistry.
[199] W. Heizer,et al. A novel method for the determination of biliary clearance in humans , 2004, The AAPS Journal.
[200] Kazuya Maeda,et al. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. , 2008, Drug metabolism and pharmacokinetics.
[201] P. Langguth,et al. Caki-1 Cells as a Model System for the Interaction of Renally Secreted Drugs with OCT3 , 2008, Nephron Physiology.
[202] C. Klaassen,et al. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[203] J. Shin,et al. Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.
[204] Caroline A. Lee,et al. Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug , 2009, Clinical pharmacology and therapeutics.
[205] Thierry Lavé,et al. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. , 2009, Molecular pharmaceutics.
[206] L. Benet,et al. Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite , 2009, Clinical pharmacology and therapeutics.
[207] Wei Zhang,et al. Silencing the Breast Cancer Resistance Protein Expression and Function in Caco-2 Cells Using Lentiviral Vector-Based Short Hairpin RNA , 2009, Drug Metabolism and Disposition.
[208] Joseph W. Polli,et al. An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.
[209] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[210] E. Burchard,et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin , 2009, Pharmacogenetics and genomics.
[211] K. Brouwer,et al. Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function , 2009, Drug Metabolism and Disposition.
[212] M. McCarthy,et al. Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study , 2009, Diabetes.
[213] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[214] Bruno Stieger,et al. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. , 2009, American journal of physiology. Cell physiology.
[215] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[216] A. Schinkel,et al. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.
[217] S. Bates,et al. ABCG2: a perspective. , 2009, Advanced drug delivery reviews.
[218] Kim L R Brouwer,et al. Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors , 2009, Drug Metabolism and Disposition.
[219] G. Abecasis,et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. , 2009, Human Molecular Genetics.
[220] P. Carrupt,et al. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. , 2009, Advanced drug delivery reviews.
[221] Sara Eyal,et al. Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.
[222] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[223] Yuichi Sugiyama,et al. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.
[224] Balázs Sarkadi,et al. Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. , 2009, Advanced drug delivery reviews.
[225] K. Brouwer,et al. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. , 2009, Molecular pharmaceutics.
[226] E. van de Steeg,et al. Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1) , 2009, Drug Metabolism and Disposition.
[227] Kazuya Maeda,et al. Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments , 2009, Drug Metabolism and Disposition.